Within3, the leading Launch Intelligence™ platform for life sciences, today announced the appointment of Erin Mistry as Chief Executive Officer. Mistry brings more than 20 years of experience in global biopharma commercialization, having launched and priced more than 20 pharmaceutical products across eight therapeutic areas.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260622637053/en/
Most recently, Mistry served as Chief Commercial Officer at CorMedix, where she led the launch of DefenCath and drove the company to break-even within six months and profitability in under a year. Earlier, she held senior global leadership roles at Syneos Health and Jupiter Life Sciences, as well as industry roles at MedImmune and AstraZeneca. She serves on the Executive Policy Council at the Harvard T.H. Chan School of Public Health and is a member of the Pharma AI Council.
Jason Smith, Within3’s Chief Technology Officer, said: “Erin has spent her career on the front lines of launch and has firsthand experience of the downside of making real-time decisions with imperfect data and information. That visceral understanding that all customers also feel is exactly the perspective we need at Within3 as we scale our AI and analytics capabilities to meet the complexity our customers face every day.”
Ian McKinnon, Managing Director, Global Head of Consulting, added, “Erin hasn’t just supported the decisions our clients make — as a leader in Pharma, she’s made them. That firsthand perspective, now shaping Within3 from the top, will sharpen everything we do.”
“What sets Erin apart is rare: she’s run commercial launches, she’s built technology platforms, and she knows the consulting work that turns raw insight into the calls our clients actually have to make. Almost no leader has stood in all three places. That combination brings credibility and vision that will resonate across the industry,” added Aly Madjerich, Senior Vice President, Global Marketing.
As CEO, Mistry will drive the expansion of Within3’s Launch Intelligence™ platform and services, helping pharmaceutical teams unify fragmented data, anticipate market shifts, and act with confidence at every stage of launch. She will combine deep commercialization expertise with Within3’s proprietary technology to deliver decision-ready intelligence across the launch lifecycle.
“Over the course of my career, I’ve learned that success isn’t about having more information — it’s about having the right intelligence, the right technology, and the speed to act,” said Mistry. “Within3 is uniquely positioned to help life sciences organizations turn insights into action by connecting commercial, medical, and field teams around a shared understanding. I look forward to leading the company through its next phase, building on its strong foundation while continuing to innovate for our customers and help bring therapies to patients more effectively.”
About Within3
Within3 empowers pharma leaders to make confident and timely launch decisions. Our Launch Intelligence™ platform unifies field insights, stakeholder engagement, social, claims, and market signals into a single connected view that surfaces what matters most. Powered by a life-sciences-trained AI architecture and guided by expert strategists, Within3 helps launch teams move with clarity and speed, turning complex evidence into decisive action.
Trusted by 70+ biotechs and all of the top 20 pharmaceutical companies, Within3 is the partner modern launch leaders rely on to align teams, act faster, and accelerate outcomes across the product lifecycle.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260622637053/en/
Media gallery
